Exit Letter of Offer to the remaining public shareholders ('Residual Public Shareholders') of Claris Lifesciences Limited ('Company') for the acquisition of 22,88,697 (Twenty Two Lakh Eighty Eight Thousand Six Hundred and Ninety Seven) fully paid up Equity Shares (representing 4.19% of the paid up share capital of the Company) held by the Residual Public Shareholders of the Company, pursuant to Regulation 21 of the Securities and Exchange Board of ....

Claris Lifesciences Ltd. manufactures sterile injectables. The Company offer injectables in various delivery systems, such as glass and plastic bottles, vials, ampules, pre-filled syringes and non-PVC and PVC bags.

Exit Letter Of Offer

Delisting Announcement with respect to voluntary delisting of the equity shares of Claris Lifesciences Limited (the 'Company') from BSE Limited in accordance with the provisions of the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 as amended from time to time ('Delisting Regulations')

Announcement Under Regulation 30 (Lodr) -Updates

Exit Offer Public Announcement to the remaining public shareholders ('Residual Public Shareholders') of Claris Lifesciences Limited (the 'Company') made by Athanas Enterprise Private Limited ('AEPL' or the 'Promoter') and Claris Holdings Private Limited ('CHPL') (collectively referred to as 'Acquirers') for the acquisition of 22,88,697 (Twenty Two Lakh Eighty Eight Thousand Six Hundred and Ninety Seven) fully paid up Equity Shares (representing 4.19% ....

The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Credit Suisse Finance (India) Pvt Ltd

Disclosures Under Reg. 29 (1) Of Sebi (Sast) Regulations, 2011

The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Athanas Enterprise Pvt Ltd and Claris Holdings Pvt Ltd

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Claris Lifesciences (CLAR IN)

Exit Letter Of Offer

Announcement Under Regulation 30 (Lodr) -Updates

Announcement Under Regulation 30 (Lodr) -Updates

Disclosures Under Reg. 29 (1) Of Sebi (Sast) Regulations, 2011

Disclosures Under Reg. 31 (1) And 31 (2) Of Sebi (Sast) Regulations, 2011

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)